ReviewChemistry & biodiversity2026
Mapping the Technological and Pharmacological Landscape of Casearia sylvestris: An Evidence-Based Prospection for Wound Healing and Pain Management.
Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Casearia sylvestris Sw. (Salicaceae) is a South American medicinal plant traditionally used for the treatment of inflammatory conditions, pain, and wound healing, with its biological activity mainly attributed to clerodane diterpenes and flavonoids. This study assessed its therapeutic potential in wound repair and pain modulation by integrating patent landscaping with scientific evidence. A systematic search was conducted in the Orbit-Questel database to identify relevant patent families, complemented by a literature review in PubMed, Scopus, and Web of Science. Patents and studies reporting analgesic, anti-inflammatory, or wound-healing activities were included. Of the 41 patent documents retrieved, eight met the inclusion criteria and were classified into three main technological strategies: (i) nanostructured sprays and biofilms containing glycolic extracts of C. sylvestris; (ii) synergistic herbal combinations; and (iii) innovative formulations for oral mucositis. Some patents also described the isolation of clerodane diterpenes with cytomodulatory and antitumor properties. Among 51 screened scientific articles, seven were included, providing generally supportive but heterogeneous evidence. Despite its promising potential, limitations related to chemical standardization, methodological variability, and the lack of clinical and mechanistic studies remain, highlighting the need for further research to enable safe and effective therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.